Myopia: The Myth of Stabilization

When should myopia control treatment stop?

By: Maria Liu, OD, PHD, MPH, MBA, FAAO

Optometric Management July 16, 2025 Vol 60(6), Issue July/August 2025 Page(s): 36

Clinical Report: Myopia: The Myth of Stabilization

Overview

Emerging evidence challenges the belief that myopia treatment can safely cease once refractive stabilization is achieved in adolescence. Axial elongation may continue beyond this period, necessitating ongoing monitoring and individualized treatment strategies.

Background

Myopia management is critical due to the increasing prevalence of myopia and its associated complications, such as retinal detachment and glaucoma. Traditional beliefs about treatment cessation based on refractive stability may overlook the ongoing risk posed by axial elongation. Understanding the nuances of myopia progression is essential for optimizing patient outcomes.

Data Highlights

No numerical data provided in the article.

Key Findings

Refractive stabilization does not equate to cessation of axial elongation.
Myopia progression can continue into the 20s and 30s, even after refractive changes appear minimal.
Factors influencing myopia progression include age of onset, parental history, academic stress, and outdoor time.
Rebound phenomena can occur with abrupt cessation of treatments like atropine.
Monitoring axial length trends is crucial for determining treatment cessation.
Education on myopia biology and ongoing vigilance is essential for families.

Clinical Implications

Clinicians should adopt a data-driven approach to myopia management, focusing on axial length rather than solely on refractive changes. Ongoing monitoring and gradual tapering of treatments are recommended to mitigate risks associated with premature cessation.

Conclusion

The myth of refractive stabilization as a signal to stop myopia treatment must be replaced with a comprehensive understanding of axial stability and individual patient risk factors.

PentaVision

Optometric Management